P3 Health Partners Inc 10-Q/A for FY2021 Q3
P3 Health Partners Inc. (PIII)
About this 10-Q/A
P3 Health Partners Inc filed this 10-Q/A on November 29, 2021, covering the quarter ended September 30, 2021 (FY2021 Q3).
Headline figures
Quarter ended September 30, 2021, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net income
- $4.85M
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
stock |
||||
| stock and one-third warrant |
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
| Emerging growth company | ||||||
Page |
||||
| Part I. Financial Information | ||||
| 1 | ||||
| 2 | ||||
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 17 | ||||
| 20 | ||||
| 20 | ||||
| Part II. Other Information | ||||
| 21 | ||||
| 21 | ||||
| 22 | ||||
| 22 | ||||
| 22 | ||||
| 22 | ||||
| 22 | ||||
| Part III. Signatures | 23 | |||
Item 1. |
Interim Financial Statements. |
September 30, 2021 (Unaudited) |
December 31, 2020 |
|||||||
| ASSETS |
||||||||
| Current Assets |
||||||||
| Cash and cash equivalents |
$ | $ | ||||||
| Prepaid expenses |
||||||||
| |
|
|
|
|||||
| Total Current Assets |
||||||||
| Deferred offering costs |
||||||||
| Cash and securities held in Trust Account |
||||||||
| |
|
|
|
|||||
| Total Assets |
$ |
$ |
||||||
| |
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
| Current liabilities |
||||||||
| Accrued expenses |
$ | $ | ||||||
| Accrued offering costs |
||||||||
| Promissory note – related party |
||||||||
| |
|
|
|
|||||
| Total Current Liabilities |
||||||||
| Warrant liabilities |
||||||||
| |
|
|
|
|||||
| Total Liabilities |
||||||||
| Commitments (Note 7) |
||||||||
| Class A common stock subject to possible redemption, |
||||||||
| Stockholders’ Equity (Deficit) |
||||||||
| Preferred stock, $ |
||||||||
| Class A common stock, $ of September 2020 excluding shares subject to redemption |
||||||||
| Class B common shares, $ of September |
||||||||
| Additional paid-in capital |
||||||||
| Accumulated deficit |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Total Stockholders’ Equity (Deficit) |
( |
) |
||||||
| |
|
|
|
|||||
| Total Liabilities and Stockholders’ Equity (Deficit) |
$ |
$ |
||||||
| |
|
|
|
|||||
Three Months Ended September 30, 2021 |
Nine Months Ended September 30, 2021 |
|||||||
| General and administrative expenses |
$ | $ | ||||||
| |
|
|
|
| ||||
| Loss from operations |
( |
) |
( |
) | ||||
| |
|
|
|
| ||||
| Other income: |
| |||||||
| Interest income |
| |||||||
| Interest earned on marketable securities held in Trust Account |
| |||||||
| Change in fair value of warrant liabilities |
| |||||||
| |
|
|
|
| ||||
| Other expense, net |
| |||||||
| |
|
|
|
| ||||
| Net income (loss) |
$ |
$ |
( |
) | ||||
| |
|
|
|
| ||||
| | ||||||||
| Basic and diluted weighted average shares outstanding of Class A common stock |
| |||||||
| |
|
|
|
| ||||
| | ||||||||
| Basic and diluted net income (loss) per share, Class A Common stock |
$ |
$ |
( |
) | ||||
| |
|
|
|
| ||||
| | ||||||||
| Basic and diluted weighted average shares outstanding of Class B common stock |
| |||||||
| |
|
|
|
| ||||
| | ||||||||
| Basic and diluted net income (loss) per share, Class B Common stock |
$ |
$ |
( |
) | ||||
| |
|
|
|
| ||||
Class A Common Stock subject to possible redemption |
Class B Common Stock |
Additional Paid-in |
Retained Earnings (Accumulated Deficit) |
Total Stockholders’ |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Capital |
Equity (Deficit) |
|||||||||||||||||||||||
| Balance — January 1, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||||
| Accretion for Class A ordinary shares to redemption amount |
— | — | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
| Sale of Net |
— | — | — | |||||||||||||||||||||||||
| Net income |
— | — | — | — | — | |||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance – March 31, 2021 |
( |
) |
( |
) | ||||||||||||||||||||||||
| Net loss |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance – June 30, 2021 |
( |
) |
( |
) | ||||||||||||||||||||||||
| Net income |
— | — | — | — | — | |||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance – September 30, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Nine months Ended September 30, 2021 |
||||
| Cash Flows from Operating Activities: |
| |||
| Net (loss) |
$ | ( |
) | |
| Adjustments to reconcile net loss to net cash used in operating activities: |
| |||
| Change in fair value of warrant liabilities |
( |
) | ||
| Interest earned on investments held in Trust Account |
( |
) | ||
| Transaction costs associated with initial public offering |
| |||
| Changes in operating assets and liabilities: |
— | | ||
| Prepaid expenses |
( |
) | ||
| Accounts payable and accrued expenses |
| |||
| |
|
|||
| Net cash used in operating activities |
( |
) | ||
| |
|
|||
| Cash Flows from Investing Activities: |
| |||
| Investment of cash into trust Account |
( |
) | ||
| |
|
|||
| Net cash used in investing activities |
( |
) | ||
| |
|
|||
| Cash Flows from Financing Activities: |
| |||
| Proceeds from sale of Units |
| |||
| Proceeds from sale of Private Placement Unit |
| |||
| Repayment of promissory note – related party |
( |
) | ||
| Payment of offering costs, including underwriting discount |
( |
) | ||
| |
|
|||
| Net cash provided by financing activities |
| |||
| |
|
|||
| Net Change in Cash |
( |
) | ||
| Cash – Beginning of period |
| |||
| |
|
|||
| Cash – End of period |
$ |
| ||
| |
|
|||
| Non-Cash investing and financing activities: |
| |||
| Offering costs included in accrued offering costs |
$ | | ||
| |
|
|||
| Initial classification of Class A common stock subject to possible redemption |
$ | | ||
| |
|
|||
Balance Sheet as of February 12, 2021 ( unaudited ) |
As Previously Reported |
Adjustment |
As Restated |
|||||||||
| Class A common stock subject to possible redemption |
$ | $ | $ | |||||||||
| Class A common stock |
$ | $ | ( |
) | $ | |||||||
| Additional paid-in capital |
$ | $ | ( |
) | $ | — | ||||||
| Accumulated deficit |
$ | ( |
) | $ | ( |
) | $ | ( |
) | |||
| Total Stockholders’ Equity (Deficit) |
$ | $ | ( |
) | $ | ( |
) | |||||
| Balance Sheet as of March 31, 2021 (unaudited) |
||||||||||||
| Class A common stock subject to possible redemption |
$ |
$ |
$ |
|||||||||
| Class A common stock |
$ |
$ |
( |
) |
$ |
|||||||
| Additional paid-in capital |
$ |
$ |
( |
) |
$ |
— |
||||||
| Retained earnings |
$ |
$ |
( |
) |
$ |
( |
) | |||||
| Total Stockholders’ Equity (Deficit) |
$ |
$ |
( |
) |
$ |
( |
) | |||||
| Balance Sheet as of June 30, 2021 (unaudited) |
||||||||||||
| Class A common stock subject to possible redemption |
$ |
$ |
$ |
|||||||||
| Class A common stock |
$ |
$ |
( |
) |
$ |
|||||||
| Additional paid-in capital |
$ |
$ |
( |
) |
$ |
— |
||||||
| Retained earnings |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | |||
| Total Stockholders’ Equity (Deficit) |
$ |
$ |
( |
) |
$ |
( |
) | |||||
| Statement of Cash Flows for the Three Months Ended March 31, 2021 (unaudited) |
||||||||||||
| Initial classification of Class A common stock subject to possible redemption |
$ |
$ |
$ |
|||||||||
| Change in value of Class A common stock subject to possible redemption |
( |
) |
— |
|||||||||
| Statement of Cash Flows for the Six Months Ended June 30, 2021 (unaudited) |
||||||||||||
| Initial classification of Class A common stock subject to possible redemption |
$ |
$ |
$ |
|||||||||
| Change in value of Class A common stock subject to possible redemption |
( |
) |
— |
|||||||||
| Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit) March 31, 2021 |
As Previously Reported |
Adjusted |
As Restated |
|||||||||
| Sales of |
( |
) |
— |
|||||||||
| Sale of |
— |
|||||||||||
| Initial value of common stock subject to possible redemption at IPO date |
( |
) |
— |
|||||||||
| Change in value of common stock subject to redemption |
( |
) |
— |
|||||||||
| Accretion for Class A common stock to redemption amount |
— |
( |
) |
( |
) | |||||||
| Total stockholders’ equity (deficit) |
( |
) |
( |
) | ||||||||
| Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit) June 30, 2021 |
As Previously Reported |
Adjusted |
As Restated |
|||||||||
| Change in value of common stock subject to redemption |
( |
) |
— |
|||||||||
| Total stockholders’ equity (deficit) |
( |
) |
( |
) | ||||||||
As Previously Reported |
As Restated |
As Previously Reported |
As Restated |
As Previously Reported |
As Restated |
|||||||||||||||||||
For the Three Months Ended March 31, 2021 |
For the Three Months Ended March 31, 2021 |
For the Three Months Ended June 30, 2021 |
For the Three Months Ended June 30, 2021 |
For the Six Months Ended June 30, 2021 |
For the Six Months Ended June 30, 2021 |
|||||||||||||||||||
| Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption |
||||||||||||||||||||||||
| Basic and diluted net loss per share, Class A common stock |
$ |
— |
$ |
$ |
— |
$ |
( |
) |
$ |
— |
$ |
( |
) | |||||||||||
| Basic and diluted weighted average shares outstanding, Class B common stock subject to possible redemption |
||||||||||||||||||||||||
| Basic and diluted net loss per share, Class B common stock |
$ |
$ |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) |
$ |
( |
) | ||||||||||
| Gross proceeds |
$ | |||
| Less: |
||||
| Proceeds allocated to Public Warrants |
( |
) | ||
| Class A common stock issuance costs |
( |
) | ||
| Plus: |
||||
| Accretion of carrying value to redemption value |
||||
| |
|
|||
| Class A common stock subject to possible redemption |
$ |
Three Months Ended September 30, 2021 |
Nine Months Ended September 30, 2021 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
| Basic and diluted net income (loss) per common stock |
||||||||||||||||
| Numerator: |
||||||||||||||||
| Allocation of net income (loss), as adjusted |
$ | $ | $ | ( |
) | $ | ( |
) | ||||||||
| Denominator: |
||||||||||||||||
| Basic and diluted weighted average stock outstanding |
||||||||||||||||
| |
|
|
|
|
|
|
|
|||||||||
| Basic and diluted net income (loss) per common stock |
$ | $ | $ | ( |
) | $ | ( |
) | ||||||||
| • | Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
| • | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
| • | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
| • | in whole and not in part; |
| • | at a price of $ |
| • | upon a minimum of “30-day redemption period”) to each warrant holder; and |
| • | if, and only if, the last reported sale price of the Class A common stock equals or exceeds $ |
| • | in whole and not in part; |
| • | at a price of $ |
| • | upon a minimum of |
| • | if, and only if, the last reported sale price of our Class A common stock equals or exceeds $ |
| • | if, and only if, there is an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the |
| Description |
Level |
September 30, 2021 |
||||||
| Liabilities: |
||||||||
| Warrant Liability – Public Warrants |
1 | |||||||
| Warrant Liability – Private Placement Warrants |
3 | |||||||
| Warrant Liability – Underwriter Warrants |
3 | |||||||
Input |
February 12, 2021 (Initial Measurement) |
September 30, 2021 |
||||||||||
| Risk-free interest rate |
% | % | ||||||||||
| Trading days per year |
||||||||||||
| Expected volatility |
% | % | ||||||||||
| Exercise price |
$ | |
$ | |||||||||
| Stock Price |
$ | $ | ||||||||||
| Private Placement |
Public |
Warrant Liabilities |
||||||||||
| Fair value as of January 1, 2021 |
$ | $ | $ | |||||||||
| Initial measurement on February 12, 2021 (including over-allotment) |
||||||||||||
| Change in valuation inputs or other assumptions |
$ | $ | ( |
) | $ | ( |
) | |||||
| |
|
|
|
|
|
|||||||
| Fair value as of September 30, 2021 |
$ | $ | $ | |||||||||
| |
|
|
|
|
|
|||||||
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
Item 4. |
Controls and Procedures |
Item 1. |
Legal Proceedings |
Item 1A. |
Risk Factors. |
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds. |
Item 3. |
Defaults Upon Senior Securities |
Item 4. |
Mine Safety Disclosures |
Item 5. |
Other Information |
Item 6. |
Exhibits |
| * | Filed herewith. |
| ** | Furnished. |
FORESIGHT ACQUISITION CORP. | ||||||
| Date: November 29, 2021 | By: | /s/ Michael Balkin | ||||
| Name: | Michael Balkin | |||||
| Title: | Chief Executive Officer (Principal Executive Officer) | |||||
| Date: November 29, 2021 | By: | /s/ Gerald Muizelaar | ||||
| Name: | Gerald Muizelaar | |||||
| Title: | Chief Financial Officer | |||||
| (Principal Financial and Accounting Officer) | ||||||
EXHIBIT 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael Balkin, certify that:
| 1. | I have reviewed this Amendment No. 1 to the quarterly report on Form 10-Q of Foresight Acquisition Corp.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and |
| b) | (Paragraph omitted pursuant to Exchange Act Rules 13a-14(a) and 15d-15(a); |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 29, 2021
| /s/ Michael Balkin |
| Michael Balkin |
| Chief Executive Officer |
| (Principal Financial and Accounting Officer) |
EXHIBIT 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gerald Muizelaar, certify that:
| 1. | I have reviewed this Amendment No. 1 to the quarterly report on Form 10-Q of Foresight Acquisition Corp..; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and |
| b) | (Paragraph omitted pursuant to Exchange Act Rules 13a-14(a) and 15d-15(a); |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 29, 2021
| /s/ Gerald Muizelaar |
| Gerald Muizelaar |
| Chief Financial Officer |
| (Principal Financial and Accounting Officer) |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Amendment No. 1 to the Quarterly Report of Foresight Acquisition Corp. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission (the “Report”), I, Michael Balkin, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: November 29, 2021
| /s/ Michael Balkin |
| Michael Balkin |
| Chief Executive Officer |
| (Principal Executive Officer) |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Amendment No. 1 to the Quarterly Report of FORESIGHT ACQUISITION CORP. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission (the “Report”), I, Gerald Muizelaar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: November 29, 2021
| /s/ Gerald Muizelaar |
| Gerald Muizelaar |
| Chief Financial Officer |
| (Principal Financial and Accounting Officer) |